Sugi Predict

Sugi Predict / Compounds / SCHEMBL1716643

SCHEMBL1716643

SCHEMBL1716643

CCC(Cc1ccccc1)(C(C)=O)C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ HIF1A Q16665 1/20 0.48
▸ PTPN1 P18031 2/20 0.43
▸ PTPN2 P17706 1/20 0.43
▸ PTPRA P18433 1/20 0.43
▸ PTPRB P23467 1/20 0.43
▸ ALDH1A1 P00352 6/20 0.43
▸ RECQL P46063 1/20 0.43
▸ LMNA P02545 2/20 0.42
▸ RIPK1 Q13546 3/20 0.41
▸ MMP8 P22894 2/20 0.40
▸ ARG1 P05089 1/20 0.40
▸ ARG2 P78540 1/20 0.40
▸ PPARG P37231 1/20 0.40
▸ PPARA Q07869 1/20 0.40
▸ SLC6A2 P23975 1/20 0.39
▸ TAAR1 Q96RJ0 1/20 0.39
▸ CYP2C9 P11712 2/20 0.39
▸ CYP2C19 P33261 2/20 0.39
▸ CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7434259 0.90 SMN1; SMN2 (0.53) SMN1; SMN2HIF1APTPN1PTPN2PTPRA
SCHEMBL395522 0.90 SMN1; SMN2 (0.53) SMN1; SMN2HIF1APTPN1PTPN2PTPRA
SCHEMBL8376369 0.89 SMN1; SMN2 (0.40) SMN1; SMN2HIF1APTPN1PTPN2PTPRA
SCHEMBL28314726 0.89 SMN1; SMN2 (0.52) SMN1; SMN2HIF1APTPN1PTPN2PTPRA
SCHEMBL21269242 0.89 SMN1; SMN2 (0.52) SMN1; SMN2HIF1APTPN1PTPN2PTPRA
SCHEMBL28314732 0.89 SMN1; SMN2 (0.52) SMN1; SMN2HIF1APTPN1PTPN2PTPRA
SCHEMBL21269412 0.89 SMN1; SMN2 (0.52) SMN1; SMN2HIF1APTPN1PTPN2PTPRA
SCHEMBL21269319 0.89 SMN1; SMN2 (0.52) SMN1; SMN2HIF1APTPN1PTPN2PTPRA
SCHEMBL28315779 0.89 SMN1; SMN2 (0.52) SMN1; SMN2HIF1APTPN1PTPN2PTPRA
SCHEMBL28314708 0.87 SMN1; SMN2 (0.50) SMN1; SMN2HIF1APTPN1PTPN2PTPRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1716159-B1 BICYCLIC SILOXANE COMPOSITIONS FOR THE RELEASE OF ACTIVE INGREDIENTS MOMENTIVE PERFORMANCE MAT INC (US) 2011-07-13 — — EP claimed
EP-1697386-B1 ACTIVE INGREDIENT-RELEASING CYCLIC SILOXANES GEN ELECTRIC (US) 2007-10-10 — — EP claimed
EP-2145042-B2 TEXTILE SCENTING HENKEL AG & CO KGAA (DE) 2021-10-06 — — EP disclosed
EP-2145042-B1 TEXTILE SCENTING HENKEL AG & CO KGAA (DE) 2018-01-17 — — EP disclosed
US-20160145273-A1 PRECATALYST FOR SHIBASAKI'S RARE EARTH METAL BINOLATE CATALYSTS THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 2016-05-26 — — US disclosed
CN-101896492-B Tetriacyclodipyranyl coumarins and the anti-HIV and anti-tuberculosis uses thereof INST OF MATARIA MEDICA CHINESE 2015-05-06 — — CN disclosed
WO-2014205437-A1 PRECATALYST FOR SHIBASAKI'S RARE EARTH METAL BINOLATE CATALYSTS THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2014-12-24 — — WO disclosed
CN-103459384-A Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS INC 2013-12-18 — — CN disclosed
CN-103189076-A Deodorant composition for sulfides TAKASAGO PERFUMERY CO LTD 2013-07-03 — — CN disclosed
CN-101100470-B Tetracyclic bispyranyl coumarin compounds INST MATERIA MEDICA CAMS 2013-02-13 — — CN disclosed
CN-102459249-A Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases EXELIXIS INC 2012-05-16 — — CN disclosed
US-5800897-A Air freshener composition containing a fiber pad EASTMAN CHEMICAL COMPANY (US) 1998-09-01 — — US disclosed
US-5733934-A Antiarrythmic and cardioprotective substituted indenoylguanidines HOECHST AKTIENGESELLSCHAFT (DE) 1998-03-31 — — US disclosed
EP-0506478-B1 Piperidine derivatives LILLY CO ELI (US) 1997-09-03 — — EP disclosed
WO-1997026926-A1 AIR FRESHENER COMPOSITION CONTAINING A FIBER PAD EASTMAN CHEMICAL COMPANY (US) 1997-07-31 — — WO disclosed
EP-0738712-A1 Anti-arrhythmic and cardioprotective substituted indenoylguanidines HOECHST AKTIENGESELLSCHAFT (DE) 1996-10-23 — — EP disclosed
CN-1118347-A Benzotoudened 5-ringneterocycl, preparation and phamaceutical and diagnostic use of same HOECHST AG (DE) 1996-03-13 — — CN disclosed
US-5250542-A Prevention of side effects induced by narcotics used as analgesics such as constipation, nausea and vomiting; 1-carboxyalkyl-4-methyl-4-(3-oxyphenyl)piperidines such as alvimopan ELI LILLY AND COMPANY (US) 1993-10-05 — — US disclosed
CN-1065455-A Piperidine derivative LILLY CO ELI (US) 1992-10-21 — — CN disclosed
EP-0506478-A1 Piperidine derivatives ELI LILLY AND COMPANY (US) 1992-09-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160145273-A1 PRECATALYST FOR SHIBASAKI'S RARE EARTH METAL BINOLATE CATALYSTS TBCB, RUVBL2, RHEB SMN1; SMN2 3335/4885HIF1A 4209/4885PTPN1 4559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.